Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”

关于“罗氟司特,一种新型磷酸二酯酶 4 抑制剂,用于治疗有急性加重史的 COPD 患者”的勘误

阅读:1

Abstract

Although the relationship between muscle strength and exercise capacity has been demonstrated in dermatomyositis without lung dysfunction, little is known about the association between exercise capacity and interstitial lung disease in dermatomyositis. Eleven patients with dermatomyositis with interstitial lung disease without the manifestation of muscle weakness and 12 patients with idiopathic interstitial pneumonia underwent the 6-minute walk test (6MWT). PaO(2), creatine kinase, percentage predicted 6MWT distance (6MWD%), and SpO(2) at rest were similar between patients. Percentage predicted vital capacity, carbon monoxide diffusing capacity (DL(CO)%), and SpO(2) after 6MWT were higher and exertional dyspnea was lower in patients with dermatomyositis than in patients with idiopathic interstitial pneumonia. SpO(2) after 6MWT was positively correlated with 6MWD% in patients with dermatomyositis, while DL(CO)% and PaO(2) were positively correlated with 6MWD% in patients with idiopathic interstitial pneumonia. Lung dysfunction in dermatomyositis might not be a major limitation factor in exercise capacity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。